Mylan has announced a delay to a major company restructuring initiative that it had been planning ahead of its merger with Pfizer’s Upjohn mature brands and off-patent business, which is due to close by the end of this year following a coronavirus-related delay.
Revealing that the 2020 restructuring program had also been delayed “as a result of the COVID-19 pandemic and the related...




